II. 6 Common Problems, Comparison, and Clinical Conclusions
Every microbiome testing method has its strengths and blind spots; this chapter compares them and shows what each can genuinely do in the clinic.
"Unfortunately I am not smart enough to draw a clinical conclusion from a PDF. Instead, I have questions: was the stool sample homogenized before sampling, or was a swab used without homogenization? Stool is not homogeneous; it is difficult to produce a sample representative of the gut microbiota. Was the exposome assessed with a questionnaire? Dysbiosis is not a deviation from a presumed optimal state, but a functional bacterial matrix specific to a given sex, age, diet, and lifestyle – sustaining a stable state of health. Can we say that is established for you? – And I still have 19 more questions. My professional preparation in this area is incomplete; I must rely on my experience, which currently tells me that without identifying the complete DNA molecule, the test is unreliable."
Comparison of methods – what each is good for and what it is not
| Criterion | 16S rRNA (amplicon) | Shotgun metagenomics | QMP / Dynamap | Metabolomics |
|---|---|---|---|---|
| Identification level | Mainly genus level | Species/strain level (partial) | Species/strain level (partial) | Metabolites (functional level) |
| Relative vs. absolute | Relative (compositional) | Relative (compositional) | Absolute (quantitative) | Absolute (concentration) |
| Viruses, fungi | No | Yes (partially) | Partially | Not directly |
| Functional genes | No | Yes | Partially | Yes (metabolic pathways) |
| Contamination risk | High | Moderate | Moderate | Low (not DNA-based) |
| Pipeline sensitivity | High | Very high | High | Moderate (software/platform-dependent) |
| Inter-laboratory reproducibility | Moderate | Low–moderate | Limited experience | Good (especially NMR) |
| Average market price (2024) | €150–600 | €600–1,200+ | Not publicly available | €300–900+ |
| Turnaround time | 2–6 weeks | 4–8 weeks | Variable | 1–3 weeks |
| Clinical decision consequence | Limited | Limited | Limited, developing | Promising, developing |
| Suitable for follow-up monitoring? | Yes (same method!) | Yes (same method!) | Developing | Yes (FMT monitoring) |
| Validated clinical indication | Research, limited clinical | Research, antibiotic resistance | Experimental clinical | FMT monitoring, research |
Diagnostic comparison – Microbiota and metabolomics analysis methods by key criteria The "limited clinical decision consequence" reflects the current state of the interpretive evidence base, not a flaw of the technology [12]. This will change – but for now, this is the clinical reality.
When is testing worthwhile, and when is it not?
The following summary can be given on the current clinical utility of microbiome analyses [306]:
- Testing may be indicated: for follow-up monitoring (same method, same laboratory, same sampling protocol); within a research protocol; for specific clinical questions (e.g. antibiotic resistance gene screening in suspected hospital infection); when the result is expected to influence the therapeutic decision.
- Testing is questionable: if there is no pre-defined therapeutic consequence to the result; if interpreted as a single one-off measurement rather than longitudinal data; if compared to a previous analysis from a different laboratory; if interpreted without an individual exposome profile assessment.
- What the test cannot tell on its own: whether the patient is in dysbiosis (without context); whether FMT is likely to be effective; whether a found composition is "pathological" for the given patient; whether an observed difference causes symptoms or is an asymptomatic variant.
The future – when might microbiome diagnostics become a clinical tool?
Microbiome diagnostics is not a static field. Over the past five years, research directions pointing towards clinical applicability have visibly strengthened [306]:
- Longitudinal follow-up protocols: Rather than a single one-off measurement, serial analysis of the same patient (using the same method, laboratory, and protocol) can provide reliable trends. In FMT treatment monitoring, this is already a partially applied approach.
- Integration of functional metabolomics: Measuring microbial activity rather than microbiome composition – determining metabolic products (short-chain fatty acids, bile acids, tryptophan metabolites) from serum or stool – can bring us closer to understanding clinical effects than taxonomic profiles alone.
- Standardised reference databases: The IHMS (International Human Microbiome Standards) and similar initiatives aim to create inter-laboratory comparability. If achieved, the clinical interpretability of analyses could improve dramatically.
The realistic expectation: microbiome diagnostics will likely gain clinical validation in a few specific indications (FMT selection, antibiotic resistance screening, inflammatory bowel disease activity monitoring) over the next 5–10 years. Broad individualised decision support, however, is still far off – and the analysis that today promises otherwise is selling hope faster than evidence [306].
Batch Effect and the "In Utero Microbiome" Myth – Contamination in Clinical Practice
Batch effect is one of the most underappreciated sources of error in microbiome studies: the same sample analyzed in different labs, on different days, or with different reagent lots can produce entirely different profiles. The classic example is the neonatal "in utero microbiome": early-2010s reports suggested that the fetal gut was already colonized before birth. A 2020 reanalysis (Kennedy et al.) demonstrated that the results were largely products of laboratory background and reagent contamination – the phenomenon did not exist, only the measurement noise [335].
The clinical implication is clear: every microbiome report must be read together with the limits of the measurement technique. A result indicating "dysbiosis" may reflect a true ecological phenomenon, a methodological artifact, or any combination of the two.
Reporting Standards – The STORMS Checklist
Precisely these error possibilities led the international research community to develop formal reporting checklists. The STORMS (Strengthening The Organization and Reporting of Microbiome Studies) checklist lists 17 items that every microbiome study should report when published: sampling, storage, extraction, primer selection, sequencing platform, pipeline versions, control samples, statistical methods [306]. A study that does not report these is not suitable for clinical decision-making.
Patients should ask their testing provider: does the lab follow the STORMS standard, and are the methodological parameters available in the report? If not, the report is likely not reproducible and cannot serve as a basis for clinical decisions.
References
[12] Zmora N, Zilberman-Schapira G, Suez J et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell. 2018. Link
Sequential invasive multi-omics profiling of the mucosal-associated gastrointestinal microbiome in mice and humans during consumption of an 11-strain probiotic versus placebo showed that probiotics remained viable through gastrointestinal passage but encountered marked mucosal colonization resistance in colonized hosts. Humans displayed person-, region- and strain-specific mucosal colonization patterns predictable from baseline host and microbiome features, while stool probiotic presence was uninformative. Stool microbiome correlated only partially with mucosal microbiome. The findings challenge the empiric use of probiotics in healthy individuals.
[306] Mirzayi C, Renson A, Genomic Standards Consortium et al. Reporting Guidelines for Human Microbiome Research: The STORMS Checklist. Nature Medicine. 2021. Link
This methodological consensus from multidisciplinary microbiome researchers adapted observational and genetic epidemiology reporting guidelines into the Strengthening The Organization and Reporting of Microbiome Studies (STORMS) tool. STORMS is a 17-item checklist organized into six sections matching typical publication structure, with new elements for laboratory, bioinformatics and statistical analyses specific to culture-independent microbiome studies. The findings provide a standardized reporting framework facilitating manuscript preparation, peer review, reader comprehension and comparative analysis of microbiome studies.
[335] Lauder AP, Roche AM, Sherrill-Mix S et al. Comparison of placenta samples with contamination controls does not provide evidence for a distinct placenta microbiota. Microbiome. 2016. Link
Re-analysis of Rackaityte et al.'s data, which had reported low-level Micrococcus luteus colonization in second-trimester human fetal intestine, identified a batch effect that violated the bioinformatic decontamination method's assumptions. Correcting for this revealed Micrococcus as a contaminant rather than a true fetal-tissue signal. Particles shown in the original micrographs were too large to be Micrococcus cells, and phylogenetic analysis of cultured isolates diverged from the sequenced taxa. Overall, the primary sequence data do not support fetal-gut colonization by Micrococcus. The work reinforces the prevailing 'sterile womb' framework and highlights the need for rigorous contamination control in low-biomass microbiome studies.